OSUR
Orasure Technologies·NASDAQ
--
--(--)
--
--(--)
OSUR fundamentals
Orasure Technologies (OSUR) released its earnings on Feb 25, 2026: revenue was 26.76M (YoY -28.53%), beat estimates; EPS was -0.27 (YoY -92.86%), missed estimates.
Revenue / YoY
26.76M
-28.53%
EPS / YoY
-0.27
-92.86%
Report date
Feb 25, 2026
OSUR Earnings Call Summary for Q4,2025
- Revenue Resilience: Q4 core revenue of $26.7 million, above guidance, with stabilization in U.S. public health and international markets.
- Product Pipeline Momentum: FDA submissions for CT/NG and Colli-Pee on track for mid-2026 launches, targeting $1.5B+ CT/NG market.
- Financial Health: 41% gross margin in Q4, $199M cash, and $5M share buyback; 2026 R&D expenses expected to decline.
- Strategic Growth Drivers: Nearshoring in Africa, clinical expansion (e.g., emergency rooms), and blood proteomics solution adoption.
- Margin Expansion Potential: 30% manufacturing capacity utilization; incremental revenue will drive margin improvement through fixed cost absorption.
EPS
Actual | -0.12 | -0.16 | 0.01 | 0.03 | 0.05 | -0.02 | -0.21 | -0.14 | -0.28 | -0.26 | 0.07 | 0.21 | 0.37 | -0.07 | 0.15 | 0.27 | -0.05 | -0.01 | -0.06 | -0.14 | -0.21 | -0.26 | -0.19 | -0.27 | ||||||||||
Forecast | -0.06 | -0.095 | -0.0609 | 0.0722 | 0.0442 | 0.0523 | -0.0387 | -0.1631 | -0.1379 | -0.1309 | -0.0295 | 0.0114 | 0.1584 | -0.066 | 0.048 | 0.0875 | 0.02 | -0.0079 | -0.0767 | -0.055 | -0.1621 | -0.205 | -0.19 | -0.205 | ||||||||||
Surprise | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -100.00% | -68.42% | +116.42% | -58.45% | +13.12% | -138.24% | -442.64% | +14.16% | -103.05% | -98.62% | +337.29% | +1742.11% | +133.59% | -6.06% | +212.50% | +208.57% | -350.00% | -26.58% | +21.77% | -154.55% | -29.55% | -26.83% | 0.00% | -31.71% |
Revenue
Actual | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 31.60M | 29.26M | 48.01M | 62.85M | 58.58M | 57.61M | 53.92M | 63.57M | 67.71M | 80.23M | 116.46M | 123.08M | 154.96M | 85.44M | 89.19M | 75.88M | 54.13M | 54.34M | 39.91M | 37.45M | 29.93M | 31.24M | 27.09M | 26.76M |
Forecast | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 29.48M | 32.82M | 41.65M | 57.08M | 57.00M | 56.74M | 47.48M | 61.95M | 60.20M | 69.91M | 91.71M | 97.10M | 123.06M | 63.89M | 74.56M | 74.13M | 52.27M | 52.34M | 38.97M | 36.81M | 29.18M | 30.36M | 29.13M | 26.44M |
Surprise | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | +7.19% | -10.86% | +15.27% | +10.12% | +2.78% | +1.53% | +13.55% | +2.61% | +12.46% | +14.77% | +27.00% | +26.75% | +25.93% | +33.74% | +19.62% | +2.37% | +3.57% | +3.81% | +2.43% | +1.74% | +2.57% | +2.91% | -7.01% | +1.21% |
Earnings Call
You can ask Aime
What factors drove the changes in Orasure Technologies's revenue and profit?Did Orasure Technologies beat or miss consensus estimates last quarter?What does Orasure Technologies do and what are its main business segments?What guidance did Orasure Technologies's management provide for the next earnings period?What were the key takeaways from Orasure Technologies’s earnings call?What is the revenue and EPS growth rate for Orasure Technologies year over year?What were the key takeaways from Orasure Technologies's earnings call?What is the market's earnings forecast for Orasure Technologies next quarter?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
